Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro

A recent Gallup survey indicates a decline in the U.S. adult obesity rate to 37%, coinciding with a doubling of GLP-1 drug usage for weight loss, underscoring the drugs' rapid market penetration. This trend is significantly boosting pharmaceutical companies, with Eli Lilly reporting strong Q3 earnings and raising revenue guidance to $63 billion-$63.5 billion due to the success of its weight loss drugs Zepbound and Mounjaro, while also expanding distribution through a Walmart partnership. The burgeoning obesity drug market, projected to reach $150 billion by 2030, is fueling intense competition, exemplified by Novo Nordisk's aggressive $9 billion unsolicited bid for GLP-1 developer Metsera, attempting to outbid Pfizer and secure future innovations in the sector.

Analysis

The U.S. adult obesity rate has fallen to 37%, a significant drop linked to a doubling of GLP-1 drug usage for weight loss, now at 12.4% of adults. This rapid market penetration, particularly among women and the 50-64 age group, signals a profound shift in public health and a burgeoning market projected to reach $150 billion by 2030.

Eli Lilly (LLY) capitalized on this trend, reporting stellar Q3 earnings and raising revenue guidance to $63B-$63.5B, driven by Zepbound and Mounjaro. Their direct-to-consumer partnership with Walmart (WMT) for Zepbound under $500 further solidifies their market position and accessibility.

The competitive landscape is intensifying, highlighted by Novo Nordisk's (NVO) unsolicited $9 billion bid for GLP-1 developer Metsera (MTSR), aiming to outmaneuver Pfizer's (PFE) previous $7.3 billion deal. This M&A activity underscores the urgency among pharmaceutical giants to secure future innovations and market share in this high-growth therapeutic area, with PFE potentially losing a strategic asset.

Key Decisions for Investors

• Investors should consider the sustained growth potential of GLP-1 drug manufacturers like Eli Lilly (LLY) and Novo Nordisk (NVO), given the demonstrated efficacy and expanding market adoption.
• Monitor the competitive landscape and M&A activities, as the bidding war for Metsera (MTSR) indicates aggressive strategies to acquire innovative drug pipelines, potentially impacting Pfizer's (PFE) long-term position in the obesity market.
• Evaluate the implications of direct-to-consumer partnerships, such as LLY's with Walmart (WMT), for market access, pricing strategies, and the broader distribution model of weight loss pharmaceuticals.